PART I. FINANCIAL INFORMATION [Item 1. Financial Statements](index=4&type=section&id=Item%201%20Financial%20Statements) The company presents its unaudited condensed financial statements for the quarter ended March 31, 2020, and accompanying notes [Condensed Balance Sheets](index=4&type=section&id=CONDENSED%20BALANCE%20SHEETS) The balance sheets show a decrease in total assets and stockholders' equity from December 31, 2019, to March 31, 2020 | Metric | March 31, 2020 (in thousands) | December 31, 2019 (in thousands) | | :----------------------------- | :----------------------------- | :----------------------------- | | Cash | $1,492 | $1,936 | | Total current assets | $2,991 | $3,542 | | Total assets | $4,249 | $4,979 | | Total current liabilities | $1,455 | $1,581 | | Total liabilities | $2,175 | $2,412 | | Total stockholders' equity | $2,074 | $2,567 | | Accumulated deficit | $(98,598) | $(95,867) | [Condensed Statements of Operations and Comprehensive Loss](index=5&type=section&id=CONDENSED%20STATEMENTS%20OF%20OPERATIONS%20AND%20COMPREHENSIVE%20LOSS) The company reported increased sales and gross profit but continued to incur a net loss impacted by a deemed dividend adjustment | Metric | Three Months Ended March 31, 2020 (in thousands) | Three Months Ended March 31, 2019 (in thousands) | | :------------------------------------------ | :----------------------------------------------- | :----------------------------------------------- | | Sales | $37 | $19 | | Cost of sales | $22 | $12 | | Gross profit | $15 | $7 | | Research and development | $296 | $464 | | Selling, general and administrative | $2,045 | $1,904 | | Total operating expenses | $2,341 | $2,368 | | Net operating loss | $(2,326) | $(2,361) | | Net loss and comprehensive loss | $(2,317) | $(2,364) | | Deemed dividend-warrant price protection | $414 | $- | | Net loss attributable to common shareholders | $(2,731) | $(2,364) | | Net loss per common share | $(1.69) | $(2.01) | [Condensed Statement of Changes in Stockholders' Equity (Deficit)](index=6&type=section&id=CONDENSED%20STATEMENT%20OF%20CHANGES%20IN%20STOCKHOLDERS'%20EQUITY%20(DEFICIT)) Stockholders' equity changed due to stock issuances and warrant exercises, offset by a significant net loss for the quarter | Metric | Balance, December 31, 2019 (in thousands) | Balance, March 31, 2020 (in thousands) | | :------------------------------------ | :---------------------------------------- | :--------------------------------------- | | Common Stock (Shares) | 1,414,671 | 1,819,981 | | Common Stock (Amount) | $1 | $2 | | Additional Paid-In Capital | $98,433 | $100,670 | | Accumulated Deficit | $(95,867) | $(98,598) | | Total Stockholders' Equity (Deficit) | $2,567 | $2,074 | | Issuance of common stock, sold for cash, net | - | $1,708 | | Net loss for the three months ended March 31, 2020 | - | $(2,731) | [Condensed Statements of Cash Flows](index=7&type=section&id=CONDENSED%20STATEMENTS%20OF%20CASH%20FLOWS) Financing activities provided a significant cash inflow, partially offsetting negative operating cash flow and a net decrease in cash | Metric | Three Months Ended March 31, 2020 (in thousands) | Three Months Ended March 31, 2019 (in thousands) | | :------------------------------------------ | :----------------------------------------------- | :----------------------------------------------- | | Net cash used in operating activities | $(1,871) | $(1,948) | | Net cash provided by (used in) investing activities | $40 | $(11) | | Net cash provided by (used in) financing activities | $1,387 | $(15) | | NET CHANGE IN CASH | $(444) | $(1,974) | | CASH AT END OF PERIOD | $1,492 | $2,946 | [Note 1 - Organization and Description of Business](index=8&type=section&id=Note%201%20-%20Organization%20and%20Description%20of%20Business) SenesTech commercializes ContraPest®, a non-lethal rat fertility control product, but has sustained significant operating losses - SenesTech, Inc. develops and commercializes **ContraPest®**, a unique non-lethal fertility control product for rat populations, targeting both male and female rats to reduce reproduction[18](index=18&type=chunk)[19](index=19&type=chunk)[22](index=22&type=chunk) - **ContraPest®** is the first and only non-lethal, fertility control product approved by the EPA for rodent management, with registration in all 50 states and the District of Columbia[23](index=23&type=chunk)[24](index=24&type=chunk) - The company effected a **1-for-20 reverse stock split** on February 4, 2020, retrospectively adjusting all share and per share amounts[26](index=26&type=chunk) - SenesTech has an **accumulated deficit of $98.6 million** and cash and cash equivalents of **$1.5 million** as of March 31, 2020, and requires additional funding to continue as a going concern[27](index=27&type=chunk)[31](index=31&type=chunk)[33](index=33&type=chunk) [Note 2 - Summary of Significant Accounting Policies](index=11&type=section&id=Note%202%20-%20Summary%20of%20Significant%20Accounting%20Policies) The company outlines its significant accounting policies, including revenue recognition, leases, and stock-based compensation | Inventory Component | March 31, 2020 (in thousands) | December 31, 2019 (in thousands) | | :------------------ | :----------------------------- | :----------------------------- | | Raw materials | $1,024 | $1,035 | | Finished goods | $142 | $149 | | Total net inventory | $1,162 | $1,180 | | Expense Category | Three Months Ended March 31, 2020 (in thousands) | Three Months Ended March 31, 2019 (in thousands) | | :------------------------------ | :----------------------------------------------- | :----------------------------------------------- | | Research and development | $3 | $9 | | Selling, general and administrative | $148 | $243 | | Total stock-based compensation expense | $151 | $252 | | Potentially Dilutive Securities | March 31, 2020 | March 31, 2019 | | :------------------------------ | :------------- | :------------- | | Common stock purchase warrants | 812,963 | 321,590 | | Restricted stock unit | 5,877 | 11,895 | | Common stock options | 136,239 | 81,499 | | Total | 955,079 | 414,984 | - Effective January 1, 2019, the company adopted ASU No. 2016-02, Leases (Topic 842), recognizing right-of-use lease assets and lease liabilities on its balance sheet[67](index=67&type=chunk). As of March 31, 2020, the balance in Right to Use Asset-Long Term was **$622 thousand** and Lease Liability-Long Term was **$624 thousand**[68](index=68&type=chunk) [Note 3 - Fair Value Measurements](index=18&type=section&id=Note%203%20-%20Fair%20Value%20Measurements) Common stock warrant liabilities are measured at fair value and classified as Level 3 due to limited observable inputs - The company's common stock warrant liabilities are classified as **Level 3** in the fair value hierarchy due to limited activity or less transparency around valuation inputs[85](index=85&type=chunk) - The estimated fair value of the derivative warrant liability was **$0** at March 31, 2020, with no change in fair value recorded for the three months ended March 31, 2020[116](index=116&type=chunk) [Note 4 - Credit Risk](index=20&type=section&id=Note%204%20-%20Credit%20Risk) The company mitigates credit risk through a diverse customer base and maintains a reserve for doubtful trade receivables - The company maintained a reserve for doubtful trade receivables of **$123 thousand** at March 31, 2020, and December 31, 2019, to address potential uncollectable accounts[92](index=92&type=chunk) [Note 5 - Prepaid Expenses](index=20&type=section&id=Note%205%20-%20Prepaid%20Expenses) Prepaid expenses increased primarily due to higher director and officer insurance and NASDAQ fees | Prepaid Expense Category | March 31, 2020 (in thousands) | December 31, 2019 (in thousands) | | :----------------------- | :----------------------------- | :----------------------------- | | Director compensation | $- | $9 | | Director and officer insurance | $123 | $115 | | NASDAQ fees | $43 | $- | | Legal retainer | $25 | $25 | | Marketing programs and conferences | $73 | $80 | | Professional services retainer | $8 | $8 | | Rent | $20 | $11 | | Equipment service deposits | $- | $1 | | Engineering, software licenses and other | $5 | $8 | | Total prepaid expenses | $297 | $257 | [Note 6 - Property and Equipment](index=20&type=section&id=Note%206%20-%20Property%20and%20Equipment) Net property and equipment decreased due to depreciation and the sale of equipment, which generated a gain | Asset Category | March 31, 2020 (in thousands) | December 31, 2019 (in thousands) | | :----------------------------- | :----------------------------- | :----------------------------- | | Research and development equipment | $1,470 | $1,585 | | Office and computer equipment | $733 | $753 | | Total property and equipment, gross | $2,581 | $2,716 | | Less accumulated depreciation and amortization | $(1,945) | $(1,978) | | Total net property and equipment | $636 | $738 | | Depreciation and amortization expense (3 months) | $77 | $111 | | Gain on sale of equipment (3 months) | $15 | $- | [Note 7 - Accrued Expenses](index=20&type=section&id=Note%207%20-%20Accrued%20Expenses) Accrued expenses decreased significantly, mainly due to reduced compensation and the settlement of accrued litigation | Accrued Expense Category | March 31, 2020 (in thousands) | December 31, 2019 (in thousands) | | :----------------------- | :----------------------------- | :----------------------------- | | Compensation and related benefits | $578 | $935 | | Accrued Litigation | $- | $238 | | Board Compensation | $9 | $17 | | Personal property and franchise tax | $10 | $2 | | Other | $3 | $1 | | Total accrued expenses | $600 | $1,193 | [Note 8 - Borrowings](index=22&type=section&id=Note%208%20-%20Borrowings) Total borrowings decreased during the quarter, with balances outstanding for both short-term and long-term debt | Borrowing Category | March 31, 2020 (in thousands) | December 31, 2019 (in thousands) | | :----------------------------- | :----------------------------- | :----------------------------- | | Short-term debt | $116 | $123 | | Finance lease obligations | $120 | $155 | | Other promissory notes | $92 | $105 | | Total long-term debt | $96 | $137 | | Total borrowings (gross) | $212 | $260 | - Finance lease obligations carry interest rates ranging from **7.3% to 18.3%** and expire through April 2022[100](index=100&type=chunk). Other promissory notes have interest rates from **13.1% to 13.3%** and expire through June 2022[101](index=101&type=chunk) [Note 9 - Common Stock Warrants and Common Stock Warrant Liability](index=23&type=section&id=Note%209%20-%20Common%20Stock%20Warrants%20and%20Common%20Stock%20Warrant%20Liability) Warrant activity included new issuances from private placements and downward price adjustments resulting in deemed dividends | Warrant Type | Balance, December 31, 2019 | Issued (3 months ended March 31, 2020) | Exercised (3 months ended March 31, 2020) | Balance, March 31, 2020 | | :------------------------------------------ | :------------------------- | :------------------------------------- | :---------------------------------------- | :---------------------- | | Various (2016 and prior) | 17,059 | - | (9,375) | 7,684 | | Common Stock Offering (Nov 2017) | 143,501 | - | - | 143,501 | | Dealer Manager (Nov 2017) | 47,250 | - | (47,250) | - | | Warrant Reissue (June 2018) | 56,696 | - | - | 56,696 | | Rights Offering Warrants (Aug 2018) | 202,943 | - | - | 202,943 | | Dealer Manager (Aug 2018) | 13,393 | - | - | 13,393 | | Dealer Manager (July 2019) | 8,334 | - | - | 8,334 | | Registered Direct Offering (Jan 2020) | - | 177,500 | - | 177,500 | | Dealer Manager Warrants (Jan 2020) | - | 13,312 | - | 13,312 | | Registered Direct Offering (Mar 2020) | - | 176,372 | - | 176,372 | | Dealer Manager Warrants (Mar 2020) | - | 13,228 | - | 13,228 | | Total Outstanding Warrants | 489,176 | 380,412 | (56,625) | 812,963 | - As of March 31, 2020, the company had **812,963 shares** of common stock issuable upon exercise of outstanding common stock warrants, at a weighted-average exercise price of **$12.58 per share**[105](index=105&type=chunk) - Downward adjustments to warrant exercise prices in January and March 2020, due to registered direct offerings, resulted in deemed dividends of **$285 thousand** and **$129 thousand**, respectively, on unexercised warrants with antidilution protection[106](index=106&type=chunk)[107](index=107&type=chunk) - In March 2020, **51,414 common shares** were issued in a cashless exercise of 56,625 warrants, settling an outstanding litigation reserve of **$238 thousand**[130](index=130&type=chunk) [Note 10 - Stockholders' Deficit](index=27&type=section&id=Note%2010%20-%20Stockholders'%20Deficit) The number of common stock shares outstanding increased due to registered direct offerings and warrant exercises | Metric | March 31, 2020 | December 31, 2019 | | :------------------------------------ | :------------- | :---------------- | | Common stock issued and outstanding | 1,819,981 | 1,414,671 | - During the three months ended March 31, 2020, the company issued **405,310 shares** of common stock, including 177,500 shares from a January 2020 offering (net proceeds **$1.2 million**) and 176,372 shares from a March 2020 offering (net proceeds **$0.5 million**)[134](index=134&type=chunk)[135](index=135&type=chunk)[136](index=136&type=chunk) [Note 11 - Stock-based Compensation](index=28&type=section&id=Note%2011%20-%20Stock-based%20Compensation) Stock-based compensation expense decreased from the prior year, with significant unrecognized compensation cost remaining - As of March 31, 2020, **33,758 shares** of common stock were available for issuance under the 2018 Equity Incentive Plan[140](index=140&type=chunk) | Metric | March 31, 2020 | December 31, 2019 | | :------------------------------------ | :------------- | :---------------- | | Options Outstanding | 136,239 | 136,489 | | Weighted Average Exercise Price Per Share | $27.90 | $28.00 | | Options Exercisable | 94,298 | - | | Metric | March 31, 2020 | December 31, 2019 | | :------------------------------------ | :------------- | :---------------- | | Restricted Stock Units Outstanding | 5,877 | 5,877 | | Weighted Average Grant-Date Fair Value Per Unit | $30.28 | $30.28 | | Expense Category | Three Months Ended March 31, 2020 (in thousands) | Three Months Ended March 31, 2019 (in thousands) | | :------------------------------ | :----------------------------------------------- | :----------------------------------------------- | | Research and development | $3 | $9 | | Selling, general and administrative | $148 | $243 | | Total stock-based compensation expense | $151 | $252 | - At March 31, 2020, total unrecognized compensation cost related to unvested options and restricted stock units was **$818 thousand**, to be recognized over a weighted average period of 24 months[150](index=150&type=chunk) [Note 12 - Commitments and Contingencies](index=30&type=section&id=Note%2012%20-%20Commitments%20and%20Contingencies) The company has various lease commitments for its facilities and is involved in certain legal proceedings - An employment discrimination charge filed by a former EVP was closed by the EEOC on February 28, 2020, with **no violations found**[152](index=152&type=chunk) - The company's manufacturing facility lease in Flagstaff, Arizona, expires in December 2020, and its corporate headquarters lease in Phoenix, Arizona, expires in November 2024[154](index=154&type=chunk)[158](index=158&type=chunk) | Years Ending December 31, | Finance Leases (in thousands) | Operating Lease (in thousands) | | :------------------------ | :---------------------------- | :----------------------------- | | 2020 | $50 | $174 | | 2021 | $58 | $136 | | 2022 | $28 | $138 | | 2023 | $- | $141 | | 2024 | $- | $132 | | Total minimum lease payments | $136 | $721 | [Note 13 - Subsequent Events](index=32&type=section&id=Note%2013%20-%20Subsequent%20Events) Subsequent events include the impact of COVID-19, receipt of a PPP loan, and a public offering to raise capital - The **COVID-19 pandemic** caused a significant slowdown in field studies and sales efforts starting in March 2020, with potential impacts on future results and challenges in communicating with customers[161](index=161&type=chunk) - On April 15, 2020, the company received a **$645.7 thousand loan** under the Paycheck Protection Program (PPP) at 1.00% interest, subject to forgiveness for qualifying expenses[162](index=162&type=chunk) - A public offering closed on April 24, 2020, is estimated to generate approximately **$4.3 million in net proceeds**, intended for working capital and ContraPest commercialization[163](index=163&type=chunk)[164](index=164&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=33&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's financial condition, operating results, continued losses, and the impact of COVID-19 [Forward-Looking Statements](index=33&type=section&id=Forward-Looking%20Statements) This section identifies forward-looking statements within the report that involve risks and uncertainties - Forward-looking statements in the report cover topics such as the impacts of the **COVID-19 pandemic**, commercialization strategies, market opportunities, regulatory approvals, financial estimates (revenue, expenses, capital), R&D plans, intellectual property, and litigation[170](index=170&type=chunk) [Overview](index=34&type=section&id=Overview) SenesTech has consistently incurred significant operating losses and requires further funding to sustain operations - Through March 31, 2020, the company received **$68.9 million** in net proceeds from equity and debt financing, **$1.7 million** from licensing fees, and **$0.6 million** from net product sales[174](index=174&type=chunk) | Metric | March 31, 2020 (in thousands) | March 31, 2019 (in thousands) | | :------------------------------------ | :----------------------------- | :----------------------------- | | Net losses | $(2,700) | $(2,400) | | Accumulated deficit | $(98,600) | - | | Cash and cash equivalents | $1,500 | - | | Stock-based compensation expense | $151 | $252 | | Stock-based compensation as % of total operating expenses | 6.4% | 10.6% | - The **COVID-19 pandemic** has caused a significant slowdown in field studies and sales efforts, potentially impacting future results and increasing concerns over customer spending and government purchases[180](index=180&type=chunk) [Components of our Results of Operations](index=35&type=section&id=Components%20of%20our%20Results%20of%20Operations) The company details its financial components, including sales, operating expenses, and its focus on improving cost structure - Research and development expenses primarily include employee-related costs, product development expenses, and facility-related costs[183](index=183&type=chunk) - The company is focused on improving its cost structure, including relocating to more cost-efficient space, organizational restructuring, and improving manufacturing processes, aiming for a **50% or greater gross margin**[186](index=186&type=chunk) - As of March 31, 2020, the company had federal and state net operating loss carryforwards of approximately **$61.3 million** and **$47.8 million**, respectively, with a full valuation allowance recorded due to uncertainty of realization[192](index=192&type=chunk) [Comparison of the Three Months Ended March 31, 2020 and 2019](index=37&type=section&id=Comparison%20of%20the%20Three%20Months%20Ended%20March%2031,%202020%20and%202019) Sales and gross profit increased, while R&D expenses decreased and SG&A expenses rose due to higher professional fees | Metric | Three Months Ended March 31, 2020 (in thousands) | Three Months Ended March 31, 2019 (in thousands) | Change (in thousands) | | :------------------------------------------ | :----------------------------------------------- | :----------------------------------------------- | :-------------------- | | Sales | $37 | $19 | $18 | | Cost of sales | $22 | $12 | $10 | | Gross profit | $15 (40.5%) | $7 (39.0%) | $8 | | Research and development | $296 | $464 | $(168) | | Selling, general and administrative | $2,045 | $1,904 | $141 | | Net operating loss | $(2,326) | $(2,361) | $35 | | Interest income/expense, net | $(6) | $2 | $(8) | | Other income (expense), net | $15 | $(5) | $20 | | Net loss attributable to common shareholders | $(2,731) | $(2,364) | $(367) | - The decrease in R&D expenses was primarily due to a reclassification of certain field support employees to sales and marketing, and the cancellation of a facility lease[198](index=198&type=chunk)[199](index=199&type=chunk) - The increase in SG&A expenses was mainly driven by a **$165 thousand increase** in professional service fees, largely due to legal expenses related to litigation settlement and common stock offerings[201](index=201&type=chunk) [Liquidity and Capital Resources](index=39&type=section&id=Liquidity%20and%20Capital%20Resources) The company has a significant accumulated deficit and anticipates needing additional financing to support ongoing operations - As of March 31, 2020, the company had an accumulated deficit of **$98.6 million** and cash and cash equivalents of **$1.5 million**[206](index=206&type=chunk) - The company will need **additional funding** to continue operations, achieve profitability, and become cash flow positive, with the COVID-19 pandemic likely increasing this need due to potential delays in field studies and sales[208](index=208&type=chunk)[209](index=209&type=chunk)[211](index=211&type=chunk) | Cash Flow Activity | Three Months Ended March 31, 2020 (in thousands) | Three Months Ended March 31, 2019 (in thousands) | | :------------------------------------ | :----------------------------------------------- | :----------------------------------------------- | | Cash used in operating activities | $(1,871) | $(1,948) | | Cash provided by (used in) investing activities | $40 | $(11) | | Cash provided by (used in) financing activities | $1,387 | $(15) | | Net increase (decrease) in cash and cash equivalents | $(444) | $(1,974) | - Operating activities used **$1.9 million** in cash for both periods, primarily due to net losses[213](index=213&type=chunk)[215](index=215&type=chunk). Financing activities provided **$1.4 million** in 2020 from common stock issuances, compared to using $15 thousand in 2019[217](index=217&type=chunk)[218](index=218&type=chunk) [Critical Accounting Policies and Significant Judgments and Estimates](index=41&type=section&id=Critical%20Accounting%20Policies%20and%20Significant%20Judgments%20and%20Estimates) Critical accounting policies include revenue recognition and stock-based compensation, which requires subjective assumptions - The company adopted **ASC 606** for revenue recognition, identifying performance obligations similar to ASC 605[223](index=223&type=chunk) - Stock-based compensation expense was **$151 thousand** for the three months ended March 31, 2020, and **$252 thousand** for the same period in 2019[225](index=225&type=chunk)[228](index=228&type=chunk) - The **Black-Scholes option-pricing model** used for stock-based awards relies on subjective assumptions including expected term (simplified method), expected volatility (comparable companies), risk-free interest rate, and zero expected dividends[226](index=226&type=chunk) [Emerging Growth Company Status](index=43&type=section&id=Emerging%20Growth%20Company%20Status) SenesTech has elected to opt out of the extended transition period for complying with new accounting standards - SenesTech has irrevocably elected to **'opt out'** of the extended transition period for complying with new or revised financial accounting standards provided by the JOBS Act[229](index=229&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=43&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) No quantitative and qualitative disclosures about market risk are applicable for this reporting period [Item 4. Controls and Procedures](index=43&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2020 - The Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were **effective** as of March 31, 2020[233](index=233&type=chunk) - There were **no material changes** in the company's internal control over financial reporting during the quarter ended March 31, 2020[234](index=234&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=44&type=section&id=Item%201.%20Legal%20Proceedings) Information regarding legal proceedings is available in Note 12 of the Condensed Financial Statements [Item 1A. Risk Factors](index=44&type=section&id=Item%201A.%20Risk%20Factors) The company updated its risk factors to address the adverse impacts of the COVID-19 pandemic on its business - The **COVID-19 pandemic** has adversely affected the company's business through travel and transportation restrictions, impacting sales, field studies, and potentially manufacturing operations[238](index=238&type=chunk) - The degree to which COVID-19 may impact the company's results of operations and financial condition is **currently unknown** and depends on future developments of the pandemic and governmental responses[239](index=239&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=44&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities were reported during the quarter that were not previously disclosed [Item 3. Defaults Upon Senior Securities](index=44&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities during the period [Item 4. Mine Safety Disclosures](index=44&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) Mine safety disclosures are not applicable to the company [Item 5. Other Information](index=44&type=section&id=Item%205.%20Other%20Information) No other information is reported for the period [Item 6. Exhibits](index=45&type=section&id=Item%206.%20Exhibits) This section provides an index of exhibits filed with the Quarterly Report on Form 10-Q [SIGNATURES](index=46&type=section&id=SIGNATURES) The report is certified by the duly authorized signatures of the company's CEO and CFO

SenesTech, Inc. (NASDAQ:SNES) Q1 2020 Earnings Conference Call May 15, 2020 11:00 AM ET Company Participants Robert Blum – Lytham Partners Ken Siegel – Chief Executive Officer Tom Chesterman – Chief Financial Officer Conference Call Participants Ian Gilson – Zacks Investment Research Operator Good morning, and welcome to the SenesTech, Inc. Reports First Quarter Fiscal Year 2020 Results Conference Call. [Operator Instructions] Please also note, today’s event is being recorded. At this time, I’d like to turn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37941 SENESTECH, INC. (Exact name of registrant as specified in its charter) | Delaware | 20-2079805 | | --- | --- | | (State or oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission File Number: 001-37941 SENESTECH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 3140 N. Caden Court, Suite 1 Flagstaff, AZ 86004 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECT ...

SenesTech, Inc. (NASDAQ:SNES) Q3 2019 Earnings Conference Call November 12, 2019 5:00 PM ET Company Participants Robert Blum – Lytham Partners Ken Siegel – Chief Executive Officer Tom Chesterman – Chief Financial Officer Conference Call Participants Kevin Ellich – Craig-Hallum Ian Gilson – Zacks Investment Research Operator Good afternoon, and welcome to the SenesTech, Incorporated. Third Quarter Fiscal Year 2019 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Inst ...

| --- | --- | --- | --- | |-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | SenesTech Disclaimer SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS The following information and the statements made during this presentation contain forward-looking statements. These forward-looking statements are based on the current expectations and beliefs of the Company's management, as well as a number of assumptions concerning future events. The forward-looking statements include statements that re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37941 (State or other jurisdiction of incorporation or organization) SENESTECH, INC. 3140 N. Caden Court, Suite 1 Flagstaff, AZ 86004 (Exact name of registrant as specified in its charter) FORM 10-Q Delaware 20-2079805 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT ...

Start Time: 17:00 January 1, 0000 5:54 PM ET SenesTech, Inc. (NASDAQ:SNES) Q2 2019 Earnings Conference Call August 13, 2019, 17:00 PM ET Company Participants Ken Siegel - CEO Tom Chesterman - CFO Robert Blum - Managing Partner, Lytham Partners, LLC Phoenix Conference Call Participants Kevin Ellich - Craig-Hallum Operator Good afternoon, and welcome to the SenesTech Second Quarter Fiscal 2019 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions]. After today ...

SenesTech, Inc. (NASDAQ:SNES) Q1 2019 Earnings Conference Call May 15, 2019 5:00 PM ET Company Participants Robert Blum - Managing Partner, Lytham Partners, LLC Phoenix Loretta Mayer - Chief Scientific Officer and Chairman of the Board Kenneth Siegel - Chief Executive Officer Edward Albe - Senior Vice President of Commercialization Tom Chesterman - Chief Financial Officer Cheryl Dyer - Chief Research Officer Conference Call Participants Kevin Ellich - Craig-Hallum Capital Group LLC Operator Good day, and we ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37941 SENESTECH, INC. (Exact name of registrant as specified in its charter) Delaware 20-2079805 (State or other jurisdiction of incorpora ...